Month: January 2024

25 January 2024 Company Announcement No. 03Completion of subscription of convertible loans On 22 January 2024 the Board of Directors in Pharma Equity Group decided to issue convertible loans in accordance with the authorisation in the company’s articles of association under article 4.3.A. The convertible loans are now fully subscribed for and allow Pharma Equity Group to loan DKK 8.914.795, which has now been paid out to the company. Thus, the maximum increase of the share capital pursuant to the convertible loan is an amount of DKK 12.627.691. The main terms are described in the company’s articles of association and Company Announcement no. 01, dated 22 January 2024. The Board of Directors will inform the market about conversion of the convertible debt.For further information, please contact: Thomas Kaas Selsø, CEO of Pharma...

   Share Buyback Transaction Details January 18 – 24, 2024 January 25, 2024 – Wolters Kluwer (Euronext: WKL), a global leading provider of expert solutions, insights and services for professionals, today reports that it has repurchased 99,400 its own ordinary shares in the period from January 18, 2024, up to and including January 24, 2024, for €13.6 million and at an average share price of €137.24. These repurchases are part of the share buyback program announced on November 1, 2023, under which we intend to repurchase shares for €100 million during the period starting January 2, 2024, up to and including February 19, 2024. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2024Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2024...

GUANGZHOU, China, Jan. 25, 2024 (GLOBE NEWSWIRE) — Puyi Inc. (NASDAQ: PUYI) (“Puyi” or the “Company”), a leading third-party wealth management services provider in China, today announced it will hold an extraordinary general meeting (“EGM”) of shareholders at its executive office at 61F, Pearl River Tower, No. 15 Zhujiang West Road, Zhujiang New Town, Tianhe, Guangzhou, Guangdong Province, People’s Republic of China on February 22, 2024 at 10:00 a.m. (Beijing time). Holders of record of ordinary shares of the Company at the close of business on January 9, 2024 (New York time), or their proxy holders, are entitled to vote at the EGM or any adjournment or postponement thereof. Holders of the Company’s American depositary shares (“ADSs”) who wish to exercise their voting rights for the underlying ordinary shares must act through the...

SINGAPORE, Jan. 25, 2024 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (NASDAQ: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that its Hong Kong subsidiary has officially upgraded its Type 1 license to include virtual asset dealing service, making it one of the first mainstream online brokerage firms in Hong Kong to receive approval for such a license upgrade. This successful upgrade opens the door for providing cryptocurrency trading services to Professional Investor clients in Hong Kong through its flagship platform, Tiger Trade. By integrating Tiger Brokers’ technology-driven brokerage expertise, the company aims to offer Professional Investors in Hong Kong an unparalleled convenience of seamless trading of both traditional securities and cryptocurrencies...

Vedhæftet er finanstilsynsgodkendte vedtægter for Investeringsforeningen Wealth Invest. Eventuelle spørgsmål rettes til Adm. direktør, Lise Bøgelund Jensen på tlf. 3328 2828. Med venlig hilsen Investeringsforeningen Wealth InvestAttachment2023 11 01 Vedtægter IF Wealth Invest

(UPM, Helsinki, 25 January 2024 at 10:00 EET) – UPM will publish its Financial Statements 2023 on Thursday, 1 February 2024 at 09:30–10:00 EET. After publishing, the report will be available on the company website at www.upm.com. A webcast and a conference call for analysts and investors begin at 13:15 EET. The Financial Statements will be presented in English by President and CEO Massimo Reynaudo and CFO Tapio Korpeinen. Participants can view the webcast online through this link. Those who wish to ask questions from the management must register for the teleconference. Join the teleconference by registering here. After the registration you will be provided with phone numbers, a user ID and a conference ID to access the conference. To ask a question, press *5 on your telephone keypad to enter the queue. The webcast will be available at...

TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) — Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today provided details from its further analysis of data from the completed Phase 1 part of the ongoing BEXMAB trial. Patients are currently being enrolled in the Phase 2 of the BEXMAB trial, which is evaluating the safety and efficacy of investigational immunotherapy bexmarilimab at two dose levels (Project Optimus part), in combination with standard of care (SoC), in patients with hypomethylating agents (HMAs)-refractory or -relapsed myelodysplastic syndrome (MDS), an aggressive myeloid leukemia with very few treatment options. The...

       Fee-earning AUM up 6.5% in the quarter    HighlightsTotal AUM of $86.3bn; fee-earning AUM of $68.4bn; AUM not yet earning fees of $15.2bn Fee-earning AUM +6.5% in the quarter on a reported basis, +3.4% on a constant currency basis; 20.6%1 annualised growth over the last five years Fundraising of $3.6bn2 during the quarter, driven by two flagship strategies: Senior Debt Partners ($1.8bn) and Strategic Equity ($0.8bn). Scaling strategies raised a total of $0.9bn. Momentum continuing into final quarter of financial year Achieved fundraising ambition ahead of target; $41bn raised since 1 April 2021 Deployment of $2.9bn during the quarter, particularly strong activity within Senior Debt Partners ($1.9bn). Actionability of pipeline is increasing across a number of strategies Well capitalised and valuable balance sheet: investment...

Aktia Bank Plc Press release 25 January 2024 at 9.00 a.m. Aktia’s Financial Statement Release 2023 will be published on Thursday 8 February 2024 at 8.00 a.m. Aktia’s Financial Statement Release 2023 will be published on Thursday 8 February 2024 at 8.00 a.m. (EET). The Financial Statement Release is available at Aktia’s website www.aktia.com after the publication. Webcast from the results event A live webcast will be sent from Aktia’s results event on Thursday 8 February 2024 at 10.30 a.m. Aktia’s CEO Juha Hammarén and CFO Outi Henriksson will be presenting the results. The event will be held in English and can be seen live as a webcast or as a recording after the event at https://aktia.videosync.fi/2023-q4-results. Questions can be asked in writing during the live webcast. The presentation material in English is available at Aktia’s...

   ICG Enterprise Trust plc Q3 update for the three months ended 31 October 2023 25 January 2024              NAV per Share of 1,959p    HighlightsNAV per Share of 1,959p (31 July 2023: 1,904p); NAV per Share Total Return of 3.3% during the quarter and 3.8% over the last twelve months (5 year annualised: 15.4%) Portfolio Return on a Local Currency Basis of 0.1% during the quarter and 4.8% on an LTM basis (5 year annualised: 17.5%) Portfolio was cashflow positive during the quarter, with Realisations of £39m and New Investments of £29m Twelve Full Exits completed at a weighted average Uplift to Carrying Value of 33.7% Third quarter dividend of 8p per share (Q3 FY23: 7p). Board intends to pay total dividends of at least 32p per share for FY24 (FY23: 30p) £3.8m returned via share buybacks in 27 separate transactions during...